Results 51 to 60 of about 10,399 (159)

Interventional Mechanical Thrombectomy for Limb Salvage in Rapidly Progressive Phlegmasia Cerulea Dolens

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Mechanical thrombectomy can provide rapid, fibrinolysis‐free restoration of venous flow in phlegmasia cerulea dolens. This case highlights an unusually severe course with extensive iliofemorocaval thrombosis, rhabdomyolysis, MRI‐confirmed muscle necrosis, and arterial hypoperfusion despite anticoagulation, in which urgent intervention achieved
Johan Filo, Manuel Stern, Malte Kelm, Lucas Busch, Patricia Wischmann   +4 more
wiley   +1 more source

Intrapleural fibrinolytic therapy with alteplase in empyema thoracis in children - A prospective pilot study

Journal of Pediatric Critical Care, 2014
Objective:outcome of children treated with Intrapleural alteplase therapy in empyema thoracis Design: Prospective interventional pilot study Setting:Pediatric Critical care and Pulmonology unit at Tertiary care Hospital Subjects: All patients of empyema ...
P K Sharma, B Saikia, R Sharma, P Jain, Z Hussain, P Khilnani   +5 more
doaj   +1 more source

Comparative effectiveness of Tenecteplase and Alteplase for ischemic stroke: real-world data from a stroke center

BMC Neurology
Background Tenecteplase (TNK) and Alteplase (rt-PA) are intravenous thrombolytics used in acute ischemic stroke (AIS). While Alteplase has long been the standard of care, TNK is now also approved for AIS by both the EMA and FDA.
Toska Maxhuni, Francesca Culaj, Merve-Melis Sayar, Priyanka Böttger, Samra Hamzic, Stefan T. Gerner, Tobias Braun, Maxime Viard, Martin Juenemann, Heidrun H. Krämer, Omar AlHaj Omar   +10 more
doaj   +1 more source

Intravenous tenecteplase compared with alteplase for minor ischaemic stroke: a secondary analysis of the AcT randomised clinical trial

Stroke and Vascular Neurology
Background In ischaemic stroke, minor deficits (National Institutes of Health Stroke Scale (NIHSS) ≤5) at presentation are common but often progress, leaving patients with significant disability.
Dar Dowlatshahi, Mohammed A Almekhlafi, Tolulope Sajobi, Aleksandra Pikula, Ashfaq Shuaib, Alexandre Y Poppe, Richard H Swartz, Fouzi Bala, Ibrahim Alhabli, Aleksander Tkach, Heather Williams, Shelagh B Coutts, Nishita Singh, Anurag Trivedi, Andrew Demchuk, Gary Hunter, Brian H Buck, Faysal Benali, Bijoy Menon, MacKenzie Horn, Radhika Nair, Thalia Field, Mahesh Kate, Negar Asdaghi, Robert Sarmiento, Ayoola Ademola, Houman Khosravani, Herbert Alejandro Manosalva Alzate, Luciana Catanese   +28 more
doaj   +1 more source

Alteplase in COVID-19 severe hypoxemic respiratory failure: the TRISTARDS multicenter randomized trial

Annals of Intensive Care
Background Pulmonary intravascular thrombus formation has been widely observed in patients with respiratory failure, for example, in patients with SARS-CoV-2 infection (COVID-19).
Giovanni Landoni, Pratima Chowdary, Ferhat Meziani, Jacques Creteur, Nicolas De Schryver, Johann Motsch, Ingrid Henrichmoeller, Alain Pagès, Nuala Peter, Thierry Danays, Markus A. Weigand, the TRISTARDS Investigators   +11 more
doaj   +1 more source

Intravenous alteplase compared with standard medical treatment for stroke aged over 70 years: a secondary analysis of the HOPE randomised clinical trial

Stroke and Vascular Neurology
Background Data regarding intravenous alteplase in elderly patients with acute ischaemic stroke during 4.5 to 24 hours of onset are limited. This study aimed to investigate the effectiveness and safety of intravenous alteplase in patients aged over 70 ...
Ying Zhou, Min Lou, Shenqiang Yan, Tingyu Yi, Yaode He, Changcai Meng, Yanxing Zhang, Zuowen Zhang, Jianhua Cheng, Hezhong Ouyang   +9 more
doaj   +1 more source

Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi-center randomized trial

Scientific Reports
Worldwide, stroke is a leading cause of long-term disability in adults. Alteplase is the only approved treatment for acute ischemic stroke (AIS) and results in an improvement in a third of treated patients.
Mohamed G. Zeinhom, Mohamed Fouad Elsayed Khalil, Islam Fathallah Mohamed Kamel, Ahmed Mohamed Kohail, Sherihan Rezk Ahmed, Ahmed Elbassiouny, Ashfaq Shuaib, Omar M Al-Nozha   +7 more
doaj   +1 more source

Nerinetide Reduces Early Infarct Growth Among Stroke Patients Undergoing EVT Without Intravenous Alteplase

Stroke: Vascular and Interventional Neurology
Background Nerinetide treatment was associated with better clinical outcomes among patients with stroke undergoing endovascular treatment who were not treated with concurrent alteplase in the randomized ESCAPE‐NA1 (Efficacy and Safety of Nerinetide for ...
Nathaniel B. Rex, Johanna M. Ospel, Rosalie V. McDonough, Nima Kashani, Leon A. Rinkel, Brian H. Buck, Jeremy Rempel, Ryan A. McTaggart, Raul G. Nogueira, Alexandre Y. Poppe, Dar Dowlatshahi, Brian A. van Adel, Richard H. Swartz, Ruchir A. Shah, Eric Sauvageau, Andrew M. Demchuk, Michael Tymianski, Michael D. Hill, Mayank Goyal   +18 more
doaj   +1 more source

Tenecteplase in Ischemic Stroke: Challenge and Opportunity

Neuropsychiatric Disease and Treatment, 2022
Guangshuo Li,1 Chuanying Wang,1 Shang Wang,1,2 Yunyun Xiong,1– 3,* Xingquan Zhao1,2,* 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2China National Clinical Research Center ...
Li G, Wang C, Wang S, Xiong Y, Zhao X
doaj  

Administration of Cilostazol Prior to Intravenous Alteplase for Acute Branch Atheromatous Disease: A Report of Three Cases

Case Reports in Neurological Medicine
Patients with acute branch atheromatous disease often experience early neurological deterioration (END) in the first 24-h period, even after intravenous alteplase. Three cases treated with cilostazol, a phosphodiesterase 3-inhibitor, prior to intravenous
Eijirou Tanaka, Yoshinari Nagakane, Daiki Fukunaga, Daisuke Nakashima, Takehiro Yamada   +4 more
doaj   +1 more source